Core Viewpoint - Minsheng Health (301507.SZ) plans to establish a partnership with Hangzhou Chaodao Equity Investment Fund Management Co., Ltd. and other limited partners to create the Hangzhou Nianfeng Yijian Equity Investment Partnership, focusing on investments in the health industry, particularly around the Minsheng health industry chain [1] Group 1 - The total fundraising scale for the partnership is set at 200 million yuan [1] - The company will contribute 98 million yuan as a limited partner, accounting for 49% of the total investment [1]

Core Viewpoint - Minsheng Health (301507.SZ) plans to establish a partnership with Hangzhou Chaodao Equity Investment Fund Management Co., Ltd. and other limited partners to create the Hangzhou Nianfeng Medical Health Equity Investment Partnership (Limited Partnership) [1] Group 1: Investment Details - The total fundraising scale for the partnership is set at 200 million yuan [1] - Minsheng Health will contribute 98 million yuan as a limited partner, accounting for 49% of the total investment [1] - The funds raised will primarily be used for equity investments in the health industry, focusing on the Minsheng health industry chain [1]

Group 1 - The company, Minsheng Health, announced that its second board meeting was held on January 6, 2026, via telecommunication [1] - The meeting reviewed documents including a proposal for jointly investing with professional investment institutions to establish a fund [1]

Core Viewpoint - Minsheng Health (301507.SZ) aims to establish a partnership with Chaodao Investment and other limited partners to create a partnership enterprise, focusing on equity investments in the health industry, particularly around the Minsheng health industry chain [1] Group 1: Partnership and Investment - The partnership enterprise will raise a total of 200 million yuan for investments [1] - Minsheng Health plans to contribute 98 million yuan, representing a 49% stake in the partnership [1]

证券代码：301507 证券简称：民生健康 公告编号：2026-002 杭州民生健康药业股份有限公司 第二届董事会第十二次会议决议公告 二、董事会会议审议情况 经全体董事审议，作出如下决议： （一）审议通过了《关于与专业投资机构共同投资设立基金的议案》 经审议，董事会认为：本次与专业投资机构共同投资，以保证公司主营业务 稳健发展为基础，借助专业投资机构在股权投资领域的资源和经验优势，有利于 提升产业资源整合能力及资本运作效率，进而增强公司整体竞争实力和盈利能力。 本次投资符合公司发展战略，符合公司全体股东的利益。因此，同意公司作为杭 州年丰医健股权投资合伙企业（有限合伙）（暂定名，以企业注册登记为准）有 限合伙人，以自有资金认缴出资人民币 9,800 万元，出资占比 49%。董事会同意 授权公司经营管理层与杭州超道股权投资基金管理有限公司和其他有限合伙人 共同签署《杭州年丰医健股权投资合伙企业（有限合伙）合伙协议》，在合伙协 议约定范围内办理合伙协议涉及的相关事宜，并负责后续本次投资相关的具体推 进工作。 表决结果：9 票同意，0 票反对，0 票弃权。 具体内容详见公司同日披露于巨潮资讯网（www.cninf ...

杭州民生健康药业股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 杭州民生健康药业股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第二届董事会第八次会议，并于 2025 年 5 月 15 日召开 2024 年年度股东 大会，分别审议通过了《关于续聘公司 2025 年度审计机构的议案》，同意续聘 中汇会计师事务所（特殊普通合伙）（以下简称"中汇会计师事务所"）为公司 2025 年度财务审计机构及内部控制审计机构，聘期一年。具体内容详见公司于 2025 年 4 月 25 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于续聘 2025 年度会计师事务所的公告》（公告编号：2025-015）。 近日，公司收到中汇会计师事务所出具的《关于变更签字会计师的告知函》， 具体情况如下： 证券代码：301507 证券简称：民生健康 公告编号：2026-004 金刚锋于 2024 年 5 月 28 日受到宁波证监局的行政监管措施，因在浙江羊绒 世家服饰股份有限公司首次公开发行股票并上市的申报文件 ...

1、杭州民生健康药业股份有限公司（以下简称"公司"）拟与杭州超道股权投 资基金管理有限公司（以下简称"超道投资"、"基金管理人"、"执行事务合伙 人"）和其他有限合伙人共同签署《杭州年丰医健股权投资合伙企业（有限合伙） 合伙协议》（以下简称"合伙协议"），出资设立杭州年丰医健股权投资合伙企业 （有限合伙）（暂定名，以企业注册登记为准，以下简称"年丰医健基金"、"合 伙企业"、"基金"）。合伙企业募集的资金主要将用于大健康产业（重点围绕民 生大健康产业链）领域的股权投资。 2、本次合伙企业募集资金总规模为20,000万元，其中，公司拟作为有限合伙人 以自有资金认缴出资人民币9,800万元（以下简称"本次投资"），出资占比49%。 证券代码：301507 证券简称：民生健康 公告编号：2026-003 杭州民生健康药业股份有限公司 关于与专业投资机构共同投资设立基金的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 特别提示： 3、根据《深圳证券交易所创业板股票上市规则》《上市公司重大资产重组管理 办法》等相关规定，本次投资事项不构成关联交易，不构成《上 ...

Core Viewpoint - On January 8, a total of 8 companies announced progress related to stock buybacks, with 5 companies disclosing ongoing buyback implementations and 3 companies completing their buyback plans [1] Group 1: Buyback Implementation Progress - The companies with the highest buyback amounts are Jian Sheng Group, Dongcheng Pharmaceutical, and Minsheng Health, with buybacks of 118 million, 17.1863 million, and 14.9993 million respectively [1] - As of January 8, 29 buyback plans have been completed this year, involving 22 companies, with 7 companies having completed buybacks exceeding 100 million [1] Group 2: Completed Buybacks - The companies that completed buybacks exceeding 10 million on that day are Jingxin Pharmaceutical, Huachangda, and Shibu Detection, with completed buybacks of 609 million, 41.8996 million, and 31.9512 million respectively [1] - The leading companies in terms of completed buyback amounts are BOE Technology Group, Jingxin Pharmaceutical, and New Hualian, with completed buybacks of 1.5 billion, 609 million, and 556 million respectively [1]

Group 1 - The core point of the article is that Minsheng Health has announced the implementation status of its second share repurchase plan, indicating a commitment to returning value to shareholders [2] - As of December 31, 2025, the company has repurchased a total of 996,900 shares, which represents 0.28% of the current total share capital [2] - The highest transaction price for the repurchased shares was 15.67 yuan per share, while the lowest was 14.39 yuan per share, with a total payment amounting to 14,999,327.00 yuan excluding transaction fees [2]

Core Viewpoint - Minsheng Health (301507.SZ) has repurchased a total of 996,900 shares, representing 0.28% of the company's total share capital, as of December 31, 2025 [1] Summary by Relevant Categories Share Repurchase - The company has conducted share repurchases through a dedicated securities account using centralized bidding transactions [1] - The highest transaction price for the repurchased shares was 15.67 yuan per share, while the lowest was 14.39 yuan per share [1] - The total amount paid for the repurchased shares was 14,999,327.00 yuan, excluding transaction fees [1]